LOS ANGELES, June 4, 2025 — Manhattan West, a modern investment firm offering a fully integrated platform of wealth management services and proprietary alternative investments, is pleased to announce the appointment of Kevin Cohen as Managing Director of the firm’s Late-Stage Venture Capital group. A pioneer in the secondary venture market, Cohen brings nearly two decades of experience in sourcing and executing strategic investments in high-growth private companies.

Cohen joins Manhattan West following a distinguished career at Manhattan Venture Partners (MVP), where he served as Partner and played an instrumental role in building one of the most recognized platforms in the secondary venture market. During his tenure, Cohen played a key role in helping MVP complete over $2 billion in transaction volume, carving a path for investor access to pre-IPO companies and providing liquidity solutions for shareholders.

“Having been instrumental in building successful secondary businesses at both Wedbush Securities and MVP, I’m thrilled about this next chapter,” said Cohen. “I’m particularly excited to join Manhattan West’s exceptional team and build upon the strong foundation the firm has already established.”

As Managing Director, Cohen will lead Manhattan West’s initiatives in the late-stage venture and secondary markets, expanding the firm’s presence in a rapidly evolving sector. His appointment marks a significant milestone in the firm’s commitment to delivering differentiated investment opportunities in the private markets.

“The secondary market for late-stage venture has never been more vital,” Cohen added. “As companies stay private longer, there’s growing demand for thoughtful, strategic liquidity solutions—especially for early investors, employees, and founders. It’s a pivotal time to be operating in this space.”

Lorenzo Esparza, CEO and Founding Principal of Manhattan West, commented on the appointment, saying, “Kevin’s addition reflects our continued commitment to expanding Manhattan West’s investment platform. We’re focused on providing our clients with access to compelling, differentiated opportunities across a broad range of asset classes, and venture capital remains a key pillar in that strategy.”

Cohen’s background spans institutional trading, venture capital, and private market investing. Before MVP, he was Senior Vice President and Head of the Private Company Strategies Group at Wedbush Securities, where he executed some of the earliest direct secondary investments in companies such as Facebook, Twitter, and LinkedIn. Earlier in his career, he held roles at Merrill Lynch and Wedbush’s Institutional Equities group, with a focus on the technology, media, and consumer sectors.

“With cutting-edge breakthroughs emerging from sectors like artificial intelligence, space exploration, and defense tech, I believe we’re still in the early innings of what will be a transformative and prosperous era for growth investing,” said Cohen. “Money managers, both professional and individual, are increasingly turning to private markets for outsized returns—a trend that shows no sign of slowing.”

Cohen holds a B.S. in Business Administration from Washington University in St. Louis, and has passed FINRA Series 7, 63, 65, and 55 exams. He resides in Manhattan Beach, CA, with his wife and two sons.

About Manhattan West
Manhattan West is a wealth management and alternative investment firm for individuals and institutions founded by former J.P. Morgan executives. One of the firm’s key value-adds comes from exclusive access to direct, private investment opportunities. Contrary to many firms that only outsource underwriting work to external fund managers, Manhattan West also internally sources, underwrites, finances, and executes transactions with a key focus on private equity and venture capital. Clients benefit from an increased investment opportunity landscape and can selectively add exposure to a broad spectrum of asset classes to their investment portfolios.

Media Contact:
Jim McCoy
Chief Operating Officer
[email protected] 

SOURCE Manhattan West

Expedition Growth Capital leads growth equity funding to accelerate Fabriq’s global expansion

BOSTON, June 4, 2025 — Fabriq, the Lean Daily Management (LDM) SaaS platform empowering frontline manufacturing teams, today announced that it has closed a $25 million growth equity investment led by Expedition Growth Capital, alongside existing investor OSS Ventures. Fabriq will use the funding to accelerate hiring, scale sales efforts in Europe and North America, and advance product development to become the operating system of the shop floor.

“In manufacturing, especially in regulated industries like pharma or aerospace, every detail matters from daily targets to long-term performance goals,” said Octave Lapeyronie, co-founder and CEO of Fabriq. “Yet too often, frontline teams are expected to drive excellence without the right tools. Fabriq changes that. We give teams the structure, visibility and agility they need to act fast and improve. With this new funding, we’re accelerating our roadmap toward an AI-powered shop floor operating system that supports every layer of operations.”

Despite industry-wide investments in machinery, manufacturers have underinvested in their people. Most frontline teams still rely on outdated tools such as Excel, SharePoint and whiteboards for daily operations. As a result:

• Wasted time on administrative tasks instead of problem-solving.
• Issues go unnoticed or are solved repeatedly with no data trail.
• Continuous improvement efforts stall, and engagement suffers.

This productivity gap has only widened amid reshoring efforts and a growing talent crisis. The World Economic Forum predicts that 44% of workers’ skills will be disrupted within the next five years, pressuring manufacturers to equip frontline teams with the right tools for continuous improvement that fosters innovation.

“Fabriq helps frontline teams move faster, work smarter, and scale operational excellence—exactly what manufacturers need as they face rising complexity and labor pressure,” said Steven Twomey, Partner at Expedition Growth Capital, who is joining Fabriq’s board of directors. “Its strong adoption by global brands and high user satisfaction reflect the quality of the product and the urgency of the problem it solves.”

Founded in 2019, Fabriq enables manufacturers to scale operational excellence by digitizing lean management practices and giving frontline teams modern, intuitive tools. Deployed across 600+ sites in 43 countries and used by organizations such as Bel, Collins Aerospace, Danone, Safran, Airbus, Medtronic, Merck and LVMH Fragrance Brands, Fabriq helps organizations achieve more reliable operations, less scrap and less downtime.

“At Medtronic, we’ve embarked on an exciting journey to deploy Fabriq across 13 manufacturing sites in the EMEA region,” said Didier Perrin, VP Manufacturing in Global Operations at Medtronic. “In a few months, we’ve successfully digitized our tier management processes, fostering engagement, building meaningful connections from operators to leaders, and driving significant efficiencies. Fabriq is more than just a digital tool; it’s a catalyst for rapid and effective standardization across all sites.”

To learn more about how Fabriq can transform manufacturing operations, visit Fabriq’s solutions page. Interested job candidates, especially in Boston, can explore opportunities to support Fabriq’s growth.

About Fabriq
Fabriq empowers manufacturing organizations to meet daily performance targets, drive continuous improvement, and scale operational excellence. The platform digitizes daily management for frontline teams, delivering a 30% boost in productivity through more reliable operations and better team engagement. Fabriq is deployed across 43 countries by organizations including Scania, John Deere, Elanco, Bulgari, Renault, and Collins Aerospace.

To learn more or request a demo, visit www.fabriq.tech

About Expedition Growth Capital
Expedition is a software specialist growth equity firm, with offices in London and Boston. Expedition partners with ambitious, rapidly growing software companies that have achieved significant traction with little or no external funding. The firm brings capital for growth initiatives and shareholder liquidity, highly relevant operational expertise, and a trusted track record of respectfully partnering with founders on their path to category leadership. For more information, please see Expedition.capital or follow Expedition on LinkedIn.

Media Contacts
Fanny Guillou
Fabriq
[email protected]

Jake Doll
PANBlast
[email protected]

SOURCE Fabriq

Led by Paladin Capital Group and Crosspoint Capital Partners, MIND is already serving Fortune 1000 companies across diverse industries

SEATTLE, June 4, 2025 — MIND™, the upcoming leader in data loss prevention (DLP), today announced $30M Series A funding, just seven months after emerging from stealth, led by Paladin Capital Group and Crosspoint Capital Partners with participation from Okta Ventures and existing investor YL Ventures. This round brings MIND’s total funding to over $40M and will fuel MIND’s strategic growth and enhance its data security platform capabilities.

In the past seven months, MIND has achieved 500% customer growth, gained significant traction among Fortune 1000 companies, prevented sensitive data loss across hundreds of thousands of endpoints through its proprietary endpoint agent and delivered immediate value by protecting the sensitive data of leading enterprises. Recently, MIND was named one of the top 10 finalists – and the only DLP startup – for the 20th annual RSAC™ 2025 Conference Innovation Sandbox contest.

“MIND was founded to help organizations thrive in the AI era and navigate the exponential growth of sensitive data in complex IT environments,” said Eran Barak, Co-Founder and CEO of MIND. “Our rapid growth reflects a clear market shift toward smarter, faster and fully automated approaches to DLP and insider risk. This funding validates both our product and the market demand. With the backing of our new investors, each bringing deep expertise in data security, we’re positioned to revolutionize the DLP category, empower secure innovation and double our R&D and go-to-market teams by year’s end.”

Organizations are overwhelmed by a surge in unstructured data and legacy DLP tools can’t keep up. They rely on manual policies, produce excessive false positives and lack the context to detect real risk. In 2024, over 1.7 billion individuals were affected by data breaches, with the average breach costing $4.88 million, marking a 10% increase from the previous year and the highest ever recorded. In addition, insider risk is top of mind for every organization with the current macro environment, corporate and federal layoffs, and high-profile incidents with North Korean IT workers and manipulated employees, such as the recent data breach at Coinbase. For security teams, the pressure is higher than ever. Real-time insider threat detection and rapid response are no longer optional; they’re essential.

As the first AI-native DLP platform, MIND puts DLP and insider risk management (IRM) programs on autopilot to autonomously find sensitive data, fix data risk issues and stop data leaks at machine speed. MIND takes a unique approach by combining data security posture and data loss prevention in one unified platform. MIND AI, the company’s multi-layer classification engine, delivers posture through the discovery and classification of sensitive data that matters and reduces DLP false positives to nearly zero. It automates workflows to enable security teams to proactively remediate data risks with minimal manual effort. Prevention starts with the real-time detection and blocking of attempts – whether malicious or inadvertent – to exfiltrate sensitive data out of an organization’s digital environments. MIND’s immediate and autonomous decision-making uses both the sensitivity of the content, combined with the understanding of the business context, to determine normal user behaviors versus high-risk behaviors that should be stopped.

“AI is transforming how enterprises access and leverage data – but also how they lose it. As large language models make sensitive data instantly available to employees through natural language prompts, DLP has re-emerged as a critical, hair-on-fire problem. MIND has built an AI-native solution designed for this new era, unifying real-time posture and prevention in a single, modern platform,” said Gibb Witham, Senior Vice President, Paladin Capital Group. “Led by Eran and his team, who have built some of the most successful machine learning–driven cybersecurity automation companies of the past decade, MIND has quickly established itself as the market leader in protecting sensitive enterprise data and redefining DLP for the age of AI.”

“As the former CEO of Symantec, which, at the time, led the market for CASB and DLP, it’s clear that today’s existing tools need to evolve in this new AI era. Enterprises need a modern and unified approach to DLP, and MIND is delivering a much-needed solution,” said Greg Clark, Managing Partner, Crosspoint Capital Partners. “We were impressed with the company’s capabilities at this year’s RSAC Innovation Sandbox contest, and with Crosspoint Capital’s investment in its team and technology, we are confident MIND will continue to deliver the industry’s most cutting-edge DLP platform. It’s time for an AI-led disruption to legacy DLP.”

“MIND is not just improving DLP, they are fundamentally transforming it,” said Justin Somaini, Partner at YL Ventures, who led MIND’s seed round and participated in this Series A. “This fundraise signals that the market is ready for a new generation of data protection built for the AI era. We are doubling down on MIND because we believe they have the vision, technology and team to redefine how enterprises safeguard their most sensitive data. This is a pivotal moment, and MIND is perfectly positioned to lead the future of DLP.”

For more information, visit www.mind.io.

About MIND
MIND is on a mission to help organizations thrive in a digital world in the AI era by protecting their most sensitive data, mitigating risks and preserving brand reputation. MIND is the first-ever data security platform that puts data loss prevention (DLP) and insider risk management (IRM) programs on autopilot to deliver both data security posture and data loss prevention. We enable businesses to mind what really matters—their most sensitive data. Founded and led by cybersecurity leaders and industry veterans, MIND is based out of Seattle, WA. For more information, contact us at [email protected].

Media Contact:
Michelle Kearney
Hi-Touch PR
443-857-9468
[email protected]

SOURCE MIND

Revenue-based transaction will fund expansions of the Michigan-based company through an innovative, shareholder-friendly financing structure

WARREN, Mich., June 3, 2025 — Conquest Flamebar, a leading provider of fire-rated duct and fire-rated A2L refrigerant enclosures, has secured a multi-million dollar growth investment from Decathlon Capital Partners. The funding will be used to support capacity expansion and fuel the company’s ongoing growth initiatives. Further details of the transaction were not disclosed.

Headquartered in Warren, MI, Conquest Flamebar specializes in delivering code compliant fire-rated architectural and engineered duct systems for infrastructure projects across a variety of industries. With proven experience, globally recognized approvals, and advanced manufacturing capabilities, the company helps ensure the safety of building occupants and first responders in the event of fire in commercial and industrial building systems.

James Miller, CEO of Conquest Flamebar, said the company is committed to advancing fire protection solutions that meet the highest industry standards. “At Conquest, we are focused on delivering fire-rated duct systems that are tested and rated to rigorous standards,” Miller said. “From design through delivery we take pride in supporting the success of our customers’ projects and are excited to continue growing our capabilities to meet rising demand.”

Thomas Webster, Managing Partner at Pacific Growth Investors, said the funding provides Conquest Flamebar with resources needed to capitalize on growing market opportunities. “This investment gives Conquest the flexibility to scale operations and meet increasing demand while maintaining full control over the company’s future,” Webster said.

John Borchers, Managing Director of Decathlon Capital Partners, expressed excitement about supporting Conquest’s next phase of growth. “Conquest Flamebar has built a strong reputation for quality, reliability, and innovation in the fire protection space,” Borchers said. “We’re proud to support their expansion efforts and look forward to seeing their continued success.”

About Conquest Flamebar
Conquest Flamebar specializes in manufacturing fire-rated duct and A2L enclosure systems for a wide range of commercial, industrial, and multi-family residential projects. With a commitment to precision, performance, and occupant safety, Conquest provides solutions that meet the highest global standards. The company is headquartered in Warren, Michigan. Learn more at www.conquestflamebar.com.

About Decathlon Capital Partners
Decathlon Capital Partners provides growth capital for companies seeking alternatives to traditional equity investment. Through the use of highly customized growth-debt financing solutions, Decathlon provides long-term growth capital without the dilution, loss of control and operational overhead that often comes with equity-based funding. With offices in Palo Alto and Park City, Decathlon is active across a wide range of sectors and geographies. Learn more at www.decathloncapital.com.

SOURCE Flamebar

ANN ARBOR, Mich., June 3, 2025 — Akadeum Life Sciences, a pioneer in buoyancy-based cell separation technology, today announced the successful close of a $20 million+ financing round. The round was led by Michigan Capital Network, with strong participation from Arboretum Ventures, NYBC Ventures, and other investors.

This capital infusion comes at a pivotal moment for Akadeum, following the recent launch of a GMP-compliant product suite designed for use in clinical trials—a critical step in advancing next-generation cell therapies. The company also recently unveiled the integration ability of microbubbles to go into many existing cell therapy manufacturing tools.

“We’re grateful for the support of our investors, who share our belief in a future where everyone can access transformative cell therapies—a future that requires better cell separation technology to unleash its full potential” said Brandon McNaughton, PhD, CEO and Founder of Akadeum.

The funding will be used to scale commercial operations and especially support customers entering clinical trials. Akadeum has gained strong industry momentum, with growing interest from leading biopharma and partners including Catalent, Charles River Laboratories, ElevateBio, and Lonza, who have featured Akadeum’s technology in recent conference talks and poster sessions.

“Akadeum is delivering some of the most innovative and disruptive technologies we’ve seen in this space,” said Paul D’Amato, CEO and Managing Director at Michigan Capital Network. “With the company recently winning the Disruptor of the Year Award during Advanced Therapies Week, word is spreading about Akadeum’s platform which is redefining how cells are isolated and prepared for therapeutic use. We’re proud to support this next stage of growth.”

Akadeum’s proprietary platform has already demonstrated therapeutic relevance, including successful use in preclinical animal models for cancer treatment, and is poised for broader adoption in human cell therapy pipelines. The company is seeing adoption due to high-impact data returning from customers.

“The data speaks for itself: Akadeum’s platform consistently delivers more viable cells, higher yields, and easier workflows compared to conventional methods, which are critical advantages in therapeutic manufacturing,” said Dan Kidle, Managing Partner at Arboretum Ventures. “This kind of performance isn’t just incremental—it’s transformative and why we are seeing rapid adoption and commercial momentum. Akadeum’s commitment to quality, scalability, and preserving cell health is setting a new benchmark for the industry.”

About Akadeum
Akadeum Life Sciences is pioneering flotation-based separation technologies that enable more effective, scalable, and gentle cell isolation. As the first to commercialize flotation-based cell separation, Akadeum has introduced industry-first innovations—including scalable negative selection, multiplex separation, microbubble-based nucleic acid extraction, and the highest-capacity T cell separation chamber ever built. Driven by a mission to advance human health, Akadeum envisions a world where innovative separations empower researchers and clinicians to unlock breakthroughs in diagnostics, therapeutics, and basic research.

Media Contact: Brandon McNaughton, CEO, [email protected]

SOURCE Akadeum Life Sciences Inc

SAN FRANCISCO, June 3, 2025 — Vector AIS, the modern fund administrator purpose-built for closed-end alternative investment funds, is excited to announce that John Spiridis will join the firm as Senior Vice President, Enterprise Growth & Services, beginning in early June.

John brings over two decades of experience spanning fund administration and private markets operations, having held senior roles at industry-leading firms including Credit Suisse, Citco, BNY Mellon, TPG, and most recently Man Varagon. With deep expertise across both the GP and fund administrator perspectives, John is uniquely positioned to help guide Vector’s next phase of growth and platform evolution.

As Vector continues expanding its footprint across private equity and adjacent private market strategies, John’s appointment underscores the firm’s commitment to building strategic infrastructure and capabilities that scale with client needs. In his new role, John will lead efforts to strengthen Vector’s private equity service offering, refine go-to-market strategies, and support cross-functional growth initiatives across product, delivery, and business development.

“We’re thrilled to welcome John to the team,” said Molly Yakubian, CEO. “His background, values, and vision align closely with where we’re headed as a company. John’s experience on both sides of the private markets ecosystem gives him an exceptional ability to see around corners and ensure we scale intentionally, sustainably, and always with the client at the center.”

John’s mandate will span asset classes, with an initial focus on private equity. He will also play a key role in shaping the roadmap for Valence, Vector’s proprietary technology platform, and in fostering strategic partnerships, referral relationships, and industry visibility through thought leadership.

Known for his collaborative approach and emphasis on team culture, John is already resonating with Vector’s values and mission. “From the outset, it’s been clear that John brings not just exceptional experience, but also the energy, warmth, and curiosity that make Vector special,” said Molly.

To learn more about John Spiridis, visit his LinkedIn profile.

Contact Information

[email protected]

www.vectorais.com

https://www.linkedin.com/company/vector-ais/

SOURCE Vector AIS

SOMERVILLE, Mass., June 3, 2025 — Matterworks, Inc., the category-defining pioneer unlocking unstructured molecular data for predictive biology, today announces new Series A financing. The round was led by Lewis & Clark Partners and OMX Ventures, joined by Pillar VC, Germin8 Ventures, Intermountain Ventures, and Tarsadia, among others. The Company will use its Series A proceeds to grow its model as a service (MaaS) business and expand its machine learning and scientific operations.

Jack Geremia, Matterworks CEO and Co-Founder, “I am delighted to partner with Lewis & Clark and welcome Carolyn Fritz to the Company’s Board of Directors as we accelerate machine intelligence innovations that tackle the unsustainable cost of life science R&D.”

Carolyn Fritz, Operating Partner at Lewis & Clark Partners, “In collaboration with its customers, Matterworks has repeatedly demonstrated its AI platform provides a step change reduction in the cost and throughput of mass spec quantitation.  We are excited to partner with this team in accelerating commercialization of their transformational technology.”

Craig Asher, Managing Director from OMX Ventures, “Matterworks is leveraging AI to unlock a new data layer for biology by making mass spectrometry accessible to all biologists. It’s a shift as transformative as single-cell sequencing and we are thrilled to support this exceptional team.”

About Matterworks
Matterworks’ Large Spectral Models (LSMs) productize self-supervised machine intelligence for direct machine interpretation of molecular-omic data. Pyxis^TM, released in 2024, is the first generative AI for complete untargeted molecular annotation, unlocking new data modalities for understanding and predicting complex biological outcomes. 

About Lewis & Clark Partners
Lewis & Clark Partners is a St. Louis-based group of experienced investment professionals passionate about investing in companies at the forefront of science, health, food, and agriculture innovation. We invest in growth-stage companies poised to scale nationally or globally. As founders, operators, investors, and scientists, our seasoned investment team brings deep sector expertise and insight to every investment.

About OMX Ventures
OMX Ventures is a venture capital firm focused on investing in a new era of bioengineering and its application for better tools, medicines, foods, industrial products, and more. We specialize in early­ stage investments at the intersection of biology, big data, and Al, with a focus on therapeutics, bio tools, diagnostics, and synthetic biology platforms.

SOURCE Matterworks

Enables Agenus to accelerate development of its lead BOT/BAL programme and strategically expand into high-unmet need indications and earlier lines of treatment.

The investment underscores Zynext Ventures‘ commitment to advancing innovation in critical therapeutic areas.

PENNINGTON, N.J., June 3, 2025 — Zynext Ventures USA LLC (Zynext), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Agenus Inc., a leading US-based immuno-oncology company developing next–generation therapeutics for high-unmet need cancers.

Agenus’ lead programme comprising Botensilimab (BOT) and Balstilimab (BAL), is a next-generation immunotherapy platform designed to strengthen and sustain the immune system’s response against tumour cells. Currently in advanced clinical trials, BOT/BAL have demonstrated significant clinical activity across nine cancer types in more than 1,200 patients, including both late-stage and neoadjuvant settings.

“Our investment in Agenus aligns perfectly with our vision to advance life-changing therapies and offer novel solutions anchored on science, innovation and health to empower patients,” said Dr. Sharvil Patel, Managing Director of Zydus Lifesciences. “Our extensive global partner network will also play a key role in supporting Agenus’ entry into new indications and geographies, allowing these innovative therapies to reach more patients, faster. This collaboration will help propel Agenus’ programmes and unlock their full potential.”

In addition to capital, Zynext Ventures will bring deep expertise in data analytics and access to a broad global network of biotech, regulatory, and clinical partners. This synergistic approach aims to unlock new avenues for Agenus, enabling the company to broaden the application of its BOT/BAL programme into earlier lines of treatment and address a wider spectrum of cancers with significant unmet medical needs.

Dr. Garo Armen, Chairman and CEO of Agenus, said, “We are delighted to partner with Zynext Ventures in a truly synergistic relationship. BOT/BAL’s remarkable results across nine distinct cancers, in both late-stage and neoadjuvant settings, inspire us to push the boundaries of what is possible in oncology. Zydus’ commercial reach and expertise make them an ideal partner to accelerate the delivery of this potentially transformative therapy.”

About Zynext Ventures

Zynext Ventures is the investment arm of Zydus Lifesciences. The venture capital firm focuses on identifying and investing in promising early-stage and growth-stage companies in the healthcare sector. Zynext Ventures provides financial support, strategic guidance, and industry expertise to its portfolio companies, helping them achieve their full potential and make a meaningful impact on the lives of patients.

For more details visit: www.zynextventures.com

LinkedIn: Zynext Ventures

Twitter: @ZynextVentures

About Zydus

Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars.

For more details visit: www.zyduslife.com.

LinkedIn: @Zydusuniverse

Instagram: @ZydusUniverse

About Agenus

Agenus Inc. is a clinical-stage immuno-oncology company committed to developing immune therapies that effectively combat cancer. Leveraging proprietary scientific platforms, the company’s pipeline includes multiple checkpoint antibody candidates, vaccines, and cell therapies. Headquartered in Lexington, MA, Agenus operates globally, driving innovations to bring better cancer treatments to patients.

For more details visit: www.agenusbio.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding the planned collaboration, the development and commercialization of BOT/BAL, and anticipated timelines. Actual results may differ due to various risks and uncertainties, including regulatory approvals and other factors. Readers are encouraged to review each company’s public filings for additional information regarding potential risks and timelines.

Logo: https://mma.prnewswire.com/media/2442038/5213236/Zynext_Ventures_Logo.jpg

SOURCE Zynext Ventures

Success of the home-based care model caught the eye of notable investors, including Deerfield Management and GV (Google Ventures). 

NEW YORK, June 3, 2025 — myLaurel, a rapidly growing healthcare company delivering home-based acute and transitional care, today announced it raised additional capital and held an initial closing of $12 million from existing investors. The round is led by Deerfield Management and GV, with participation from Emerson Collective, Pinta Partners, Ochsner Health, and management.

This funding follows a record-breaking 2024 and continued growth in the first quarter of 2025, marked by a 4x year-over-year increase in new patient volume and revenue. myLaurel’s signature Acute Care at Home program continues to show strong clinical and financial outcomes for its hospital partners, most notably through its partnership with Ochsner. The new capital will enable the company to further expand with Ochsner and accelerate growth with new health system clients, focusing on scaling Acute Care at Home in both existing and new markets.

As the U.S. population continues to age, the demand for scalable, high-quality care outside the traditional hospital is growing rapidly. A recent report in JAMA warns that the country could face a “dangerous threshold” of hospital bed shortages by 2032, driven in large part by an aging population with increasingly complex medical needs. myLaurel’s model directly addresses this challenge by enabling hospitals to deliver high-acuity care in patients’ homes, improving outcomes while reducing the strain on facility throughput and capacity. 

“Our momentum reflects both the urgency of the need and the strength of our care model solution,” said Juan Vallarino, CEO of myLaurel. “In partnership with systems like Ochsner, we demonstrate that high-acuity, home-based care can provide an exceptional patient experience, reduce costs, and meaningfully extend hospital capacity. This funding round validates our vision and positions us to serve more patients with greater efficiency and impact.”

In 2024, myLaurel and Ochsner Health jointly developed the Acute Care at Home model, which has since outperformed expectations in clinical and operational metrics. The partnership has become a benchmark for how health systems can modernize care delivery for complex, frail, and elderly patients outside of traditional hospital walls.

“myLaurel is pioneering a scalable care model that addresses one of the most pressing challenges in healthcare — how to safely and effectively care for complex patients outside the hospital,” said Moses Adubi, Principal at Deerfield. “We believe myLaurel is well-positioned to lead a transformation in acute care and deliver benefits across the continuum of care.”

As the healthcare industry increasingly embraces home-based care for medically complex populations, myLaurel delivers the best of both worlds: an enhanced patient experience and improved hospital efficiency. This combination has made myLaurel a strategic partner for health systems, payers, and patients alike.

About myLaurel
myLaurel was founded on the belief that a portion of today’s hospital care can—and should—be delivered in the comfort of home.  As a tech-enabled medical group, we provide on-demand acute and transitional care to frail, elderly, or medically complex patients at home—helping them avoid the traditional care path of ambulance, ER, hospital admission, and nursing facility.  

Health systems, provider groups, and payers partner with us to reduce avoidable utilization, improve readmission rates, accelerate discharges, and enhance patient experience—all while maintaining the highest standards of care and safety. We stand behind our outcomes with our partners, putting our fees at risk to demonstrate our commitment and confidence in delivering results.  

Headquartered in New York, myLaurel delivers hands-on clinical care guided by remote physicians and supported by advanced technology, diagnostics, and therapies. The result: 33% lower ED utilization, 49% fewer readmissions, 3,000+ bed days saved per hospital annually – enabling over 640 additional acute inpatient admissions –  and a patient Net Promoter Score of 96. Learn more at mylaurelhealth.com.

About Deerfield Management

Deerfield is an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The Firm works across the healthcare ecosystem to connect people, capital, ideas, and technology in bold, collaborative, and inclusive ways. For more information, please visit www.deerfield.com.

About GV
GV supports innovative founders across multiple stages and sectors, from artificial intelligence and life sciences to consumer platforms, enterprise software, and frontier technology.

Launched as Google Ventures in 2009, GV oversees more than $10 billion in assets under management. Our operating partners support founding teams at every stage of company-building across executive talent, design, communications, and marketing. GV is a non-strategic venture capital firm that invests independently from its sole limited partner, Alphabet. We connect startups with Google and Alphabet companies, providing unique access to the world’s best technology and talent.

GV has 400 active portfolio companies spanning North America, Europe, and Israel. Our portfolio includes Lightmatter, Stripe, Treeline Biosciences, Vercel, and Wonder, with notable exits including Uber, Nest, Slack, GitLab, Duo Security, Flatiron Health, Lemonade, and One Medical. The firm is headquartered in the San Francisco Bay Area, with offices in Cambridge, New York, and London. For more information, please visit gv.com.

For more information contact:
[email protected]

SOURCE myLaurel